<DOC>
	<DOCNO>NCT01266265</DOCNO>
	<brief_summary>A surveillance respiratory tract related adverse event patient treat Tyvaso® ( treprostinil ) Inhalation Solution versus FDA approve therapy</brief_summary>
	<brief_title>Study Incidence Respiratory Tract AEs Patients Treated With Tyvaso® Compared Other FDA Approved PAH Therapies</brief_title>
	<detailed_description>A post marketing surveillance determine type incidence oro/nasopharyngeal pulmonary adverse event may occur patient treat commercially available Tyvaso® ( treprostinil ) Inhalation Solution . A comparison make type incidence event patient receive FDA approve therapy pulmonary arterial hypertension , control measure .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Clinical diagnosis PAH , WHO GROUP I Prescribed currently receive Tyvaso and/or FDAapproved therapy treatment PAH Willing able provide write informed consent Previous initiation permanent discontinuation Tyvaso Participation investigational clinical drug device trial within 30 day enrollment Current past diagnosis lung neoplasm Active gastrointestinal pulmonary bleed enrollment Planned surgical intervention treatment PAH e.g. , atrial septostomy transplant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>treprostinil sodium</keyword>
	<keyword>Tyvaso</keyword>
	<keyword>inhalation</keyword>
	<keyword>Ventavis</keyword>
	<keyword>iloprost</keyword>
	<keyword>prostacyclin</keyword>
	<keyword>epoprostenol sodium</keyword>
	<keyword>Flolan</keyword>
	<keyword>Veletri</keyword>
	<keyword>subcutaneous intravenous prostacyclin analogue</keyword>
	<keyword>Remodulin</keyword>
	<keyword>oral ERA</keyword>
	<keyword>bosentan</keyword>
	<keyword>Tracleer</keyword>
	<keyword>ambrisentan</keyword>
	<keyword>Letairis</keyword>
	<keyword>oral PDE5 inhibitor</keyword>
	<keyword>sildenafil</keyword>
	<keyword>Revatio</keyword>
	<keyword>tadalafil</keyword>
	<keyword>Adcirca</keyword>
	<keyword>Opsumit</keyword>
	<keyword>macitentan</keyword>
	<keyword>Adempas</keyword>
	<keyword>riociguat</keyword>
	<keyword>Orenitram</keyword>
	<keyword>oral treprostinil</keyword>
</DOC>